Stocks
Intellia Therapeutics, Inc.NTLA
NASDAQHealthcareBiotechnology$12.76-0.70%
Focused on developing CRISPR-based gene editing therapies, this biotech company is a leader in the field of genomic medicine. Investors closely monitor its progress due to its potential to treat genetic disorders and its partnerships with major pharmaceutical firms.
Market Cap: $1.5B52W Range: $5.90 – $28.25
Congressional Interest in Intellia Therapeutics, Inc. (NTLA)
3 members of Congress have disclosed 15 trades in Intellia Therapeutics, Inc. (NTLA), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 8 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
15
Unique Politicians
3
Buys
7
Sells
8
Who in Congress Is Trading NTLA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-08-25 | Thomas R Carper | sell | $1K – $15K |
| 2023-05-22 | Thomas R Carper | buy | $1K – $15K |